Zidovudine-based lytic-inducing chemotherapy for Epstein–Barr virus-related lymphomas
暂无分享,去创建一个
D. Dittmer | U. Bayraktar | S. Bayraktar | J. Ramos | N. Toomey | L. Cabral | D. Pereira | B. Ashlock | Luis A Diaz | Luis A. Diaz
[1] Human Herpesvirus , 2016, Red Book Atlas of Pediatric Infectious Diseases, 3rd Ed.
[2] M. Staudt,et al. Nuclear Factor kappa B (NFkB) pathway associated biomarkers in AIDS defining malignancies , 2012 .
[3] Robert M. Williams,et al. Histone deacetylase inhibitors are potent inducers of gene expression in latent EBV and sensitize lymphoma cells to nucleoside antiviral agents. , 2012, Blood.
[4] S. Steinberg,et al. High-dose zidovudine plus valganciclovir for Kaposi sarcoma herpesvirus-associated multicentric Castleman disease: a pilot study of virus-activated cytotoxic therapy. , 2011, Blood.
[5] M. Vasconcelos,et al. Treatment of Akata EBV-Positive Cells with Doxorubicin Causes More EBV Reactivation than Treatment with Etoposide , 2011, Chemotherapy.
[6] M. Gulley,et al. Translational Relevance The presence of the EBV genome within malignant cells of endemic , 2010 .
[7] S. Kenney,et al. The Epstein-Barr Virus (EBV)-Encoded Protein Kinase, EBV-PK, but Not the Thymidine Kinase (EBV-TK), Is Required for Ganciclovir and Acyclovir Inhibition of Lytic Viral Production , 2010, Journal of Virology.
[8] I. Lossos,et al. Primary CNS lymphoma in HIV positive and negative patients: comparison of clinical characteristics, outcome and prognostic factors , 2010, Journal of Neuro-Oncology.
[9] E. Cesarman,et al. HIV-associated lymphomas and gamma-herpesviruses. , 2009, Blood.
[10] L. Pantanowitz,et al. HIV‐associated plasmablastic lymphoma: Lessons learned from 112 published cases , 2008, American journal of hematology.
[11] E. Elkin,et al. Treatment patterns and prognosis in patients with human immunodeficiency virus and primary central system lymphoma , 2008, Leukemia & lymphoma.
[12] C. Klein,et al. A phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies. , 2007, Blood.
[13] T. Lawrence,et al. Antimetabolite radiosensitizers. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] D. Huhn,et al. Acquired immunodeficiency syndrome‐related lymphoma , 2006, Cancer.
[15] L. Ratner,et al. Antiviral and immunomodulatory treatment for AIDS-related primary central nervous system lymphoma: AIDS Malignancies Consortium pilot study 019. , 2006, Clinical lymphoma & myeloma.
[16] E. Cesarman,et al. Pathogenesis of viral lymphomas. , 2006, Cancer treatment and research.
[17] Y. Kasamon,et al. AIDS-related primary central nervous system lymphoma. , 2005, Hematology/oncology clinics of North America.
[18] G. Barber,et al. Azidothymidine inhibits NF-κB and induces Epstein-Barr virus gene expression in Burkitt lymphoma , 2005 .
[19] J. Mate,et al. The prognosis of HIV-infected patients with diffuse large B-cell lymphoma treated with chemotherapy and highly active antiretroviral therapy is similar to that of HIV-negative patients receiving chemotherapy. , 2005, Haematologica.
[20] M. Gulley,et al. Epstein-Barr virus quantitation by real-time PCR targeting multiple gene segments: a novel approach to screen for the virus in paraffin-embedded tissue and plasma. , 2004, The Journal of molecular diagnostics : JMD.
[21] M. Staudt,et al. The Tumor Microenvironment Controls Primary Effusion Lymphoma Growth in Vivo , 2004, Cancer Research.
[22] D. Thorley-Lawson,et al. Persistence of the Epstein-Barr virus and the origins of associated lymphomas. , 2004, The New England journal of medicine.
[23] S. Kenney,et al. Lytic Induction Therapy for Epstein-Barr Virus-Positive B-Cell Lymphomas , 2004, Journal of Virology.
[24] D. Skiest,et al. Survival is prolonged by highly active antiretroviral therapy in AIDS patients with primary central nervous system lymphoma , 2003, AIDS.
[25] W. Wilson,et al. Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology. , 2003, Blood.
[26] B. Gazzard,et al. Leptomeningeal disease in AIDS-related non-Hodgkin's lymphoma , 2003, AIDS.
[27] G. Barber,et al. Potentiation of TRAIL-induced apoptosis in primary effusion lymphoma through azidothymidine-mediated inhibition of NF-kappa B. , 2003, Blood.
[28] M. Caligiuri,et al. Experimental treatment of Epstein-Barr virus-associated primary central nervous system lymphoma. , 2003, Cancer research.
[29] H. Kantarjian,et al. Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone and highly active antiretroviral therapy for patients with acquired immunodeficiency syndrome‐related burkitt lymphoma/leukemia , 2002, Cancer.
[30] C. Fletcher,et al. Clinical Implications of CNS Penetration of Antiretroviral Drugs , 2002, CNS drugs.
[31] G. Barber,et al. Induction of a TRAIL mediated suicide program by interferon alpha in primary effusion lymphoma , 2001, Oncogene.
[32] R. Ambinder,et al. Induction of Epstein-Barr Virus Kinases To Sensitize Tumor Cells to Nucleoside Analogues , 2001, Antimicrobial Agents and Chemotherapy.
[33] S. Kenney,et al. Activation of lytic Epstein-Barr virus (EBV) infection by radiation and sodium butyrate in vitro and in vivo: a potential method for treating EBV-positive malignancies. , 2000, Cancer research.
[34] L. Boise,et al. Azidothymidine and Interferon-α Induce Apoptosis in Herpesvirus-associated Lymphomas , 1999 .
[35] R. Ambinder,et al. Human Herpesvirus 8-Encoded Thymidine Kinase and Phosphotransferase Homologues Confer Sensitivity to Ganciclovir , 1999, Journal of Virology.
[36] G. Sfakianakis,et al. Treatment of AIDS-related primary central nervous system lymphoma with zidovudine, ganciclovir, and interleukin 2. , 1999, AIDS research and human retroviruses.
[37] L. Boise,et al. Azidothymidine and interferon-alpha induce apoptosis in herpesvirus-associated lymphomas. , 1999, Cancer research.
[38] D. Sage,et al. The Epstein-Barr Virus Thymidine Kinase Does Not Phosphorylate Ganciclovir or Acyclovir and Demonstrates a Narrow Substrate Specificity Compared to the Herpes Simplex Virus Type 1 Thymidine Kinase , 1998, Antimicrobial Agents and Chemotherapy.
[39] V. Godfrey,et al. Expression of the Epstein-Barr virus latent membrane protein 1 induces B cell lymphoma in transgenic mice. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[40] D. Faller,et al. Arginine butyrate-induced susceptibility to ganciclovir in an Epstein-Barr-virus-associated lymphoma. , 1998, Blood cells, molecules & diseases.
[41] P. Pellett,et al. Human herpesvirus 6 , 1997, Clinical microbiology reviews.
[42] D. Huhn,et al. Plasmablastic lymphomas of the oral cavity: a new entity associated with the human immunodeficiency virus infection. , 1997, Blood.
[43] F. Gherlinzoni,et al. 3'-Azido 3'-deoxythymidine + methotrexate as a novel antineoplastic combination in the treatment of human immunodeficiency virus-related non-Hodgkin's lymphomas. , 1997, Blood.
[44] E. Klein,et al. Induction of the lytic viral cycle in Epstein Barr virus carrying Burkitt lymphoma lines is accompanied by increased expression of major histocompatibility complex molecules. , 1993, Immunology letters.
[45] B. Nathwani,et al. Epstein-Barr virus-associated non-Hodgkin's lymphoma in patients infected with the human immunodeficiency virus. , 1993, Blood.
[46] G. Brosch,et al. Histone deacetylase , 1993, FEBS Letters.
[47] P. Tosi,et al. Azidothymidine-induced cytotoxicity and incorporation into DNA in the human colon tumor cell line HCT-8 is enhanced by methotrexate in vitro and in vivo. , 1992, Cancer research.
[48] R. Ambinder,et al. Epstein-Barr virus in AIDS-related primary central nervous system lymphoma , 1991, The Lancet.
[49] J. Rachlin,et al. Primary central nervous system lymphomas: natural history and response to radiation therapy in 55 patients with acquired immunodeficiency syndrome. , 1990, Journal of neurosurgery.
[50] J. C. Martin,et al. 9-[(1,3-Dihydroxy-2-propoxy)methyl]guanine: a new potent and selective antiherpes agent. , 1983, Journal of medicinal chemistry.